HIV-1 Tat and Immune Dysregulation in AIDS Pathogenesis: A Therapeutic Target

被引：11

作者：

Chiozzini, Chiara ^{[1
]}

Toschi, Elena ^{[2
]}

机构：

[1] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy

[2] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy

来源：

CURRENT DRUG TARGETS | 2016年 / 17卷 / 01期

关键词：

AIDS pathogenesis; immune dysregulation; HIV-1; Tat; therapy; vaccine; HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; RECEPTOR-RELATED PROTEIN; 2ND CODING EXON; T-CELLS; KAPOSIS-SARCOMA; DENDRITIC CELLS; GROWTH-FACTOR; GENE-THERAPY; IN-VIVO;

D O I：

10.2174/1389450116666150825110658

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The HIV-1 transactivator Tat protein plays a key role in AIDS pathogenesis. Besides the Tat role as activator of HIV-1 transcription, it exerts several important functions on infected and uninfected cells. In fact, HIV-1 Tat is released by infected cells and is taken up by neighboring cells. In this way it regulates expression of viral and cellular genes and it modulates several cellular pathways leading to HIV-1 infection spreading and immune dysregulation. So far, Tat protein and the cellular pathways targeted by Tat may represent potential targets for new anti-HIV therapeutic approaches and vaccine development against AIDS.

引用

页码：33 / 45

页数：13

共 160 条

[31]

CUPP C, 1993, ONCOGENE, V8, P2231

[32] Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex [J].

D'Orso, Ivan ;

Frankel, Alan D. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) :3101-3106

[33]

Daelemans D, 2000, MOL PHARMACOL, V57, P116

[34] Genetic Variation and HIV-Associated Neurologic Disease [J].

Dahiya, Satinder ;

Irish, Bryan P. ;

Nonnemacher, Michael R. ;

Wigdahl, Brian .

ADVANCES IN VIRUS RESEARCH, VOL 87, 2013, 87 :183-240

[35] THE TRANSACTIVATOR GENE OF THE HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-III IS REQUIRED FOR REPLICATION [J].

DAYTON, AI ;

SODROSKI, JG ;

ROSEN, CA ;

GOH, WC ;

HASELTINE, WA .

CELL, 1986, 44 (06) :941-947

[36] The Ins and Outs of HIV-1 Tat [J].

Debaisieux, Solene ;

Rayne, Fabienne ;

Yezid, Hocine ;

Beaumelle, Bruno .

TRAFFIC, 2012, 13 (03) :355-363

[37] Human immunodeficiency virus type 1 Tat protein activates transcription factor NF-κB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR [J].

Demarchi, F ;

Gutierrez, MI ;

Giacca, M .

JOURNAL OF VIROLOGY, 1999, 73 (08) :7080-7086

[38] A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques [J].

Demberg, Thorsten ;

Florese, Ruth H. ;

Heath, Megan J. ;

Larsen, Kay ;

Kalisz, Irene ;

Kalyanaraman, V. S. ;

Lee, Eun Mi ;

Pal, Ranajit ;

Venzon, David ;

Grant, Richard ;

Patterson, L. Jean ;

Korioth-Schmitz, Birgit ;

Buzby, Adam ;

Dombagoda, Dilani ;

Montefiori, David C. ;

Letvin, Norman L. ;

Cafaro, Aurelio ;

Ensoli, Barbara ;

Robert-Guroff, Marjorie .

JOURNAL OF VIROLOGY, 2007, 81 (07) :3414-3427

[39] Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA [J].

Deng, LW ;

Wang, D ;

de la Fuente, C ;

Wang, L ;

Li, H ;

Lee, CG ;

Donnelly, R ;

Wade, JD ;

Lambert, P ;

Kashanchi, F .

VIROLOGY, 2001, 289 (02) :312-326

[40] HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells [J].

Deregibus, MC ;

Cantaluppi, V ;

Doublier, S ;

Brizzi, MF ;

Deambrosis, I ;

Albini, A ;

Camussi, G .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25195-25202

← 1 2 3 4 5 6 7 8 9 10 →